Search

New appeal launches to find better treatments for infections and help ensure no one with CF goes into hospital and never comes home

Cystic Fibrosis Trust has today launched a new spring appeal to fund research into CF lung infections, so more people with cystic fibrosis avoid going into hospital with lung infections and have the chance to live a life not limited by their condition.

Our reaction to the Spring Statement

Today the Chancellor has announced that the health element of Universal Credit will be cut by 50% for new claimants from 2026, and frozen for existing claimants until 2029-30. This follows proposed changes announced last week to benefits and employment support. The Trust has written to the Secretary of State for Work and Pensions, Liz Kendall MP, to highlight our concerns about the potential negative impact on people with CF of some of the changes, as well as the areas that we think could be more positive.

Trust-funded research identifies a new approach to treating Pseudomonas aeruginosa lung infections

Researchers led by Professor Martin Welch at the University of Cambridge have studied the biochemistry of the bacteria Pseudomonas aeruginosa, which causes hard-to-treat lung infections in people with CF and identified a potential new approach towards treating these infections. This work was funded by a Strategic Research Centre grant from Cystic Fibrosis Trust and has been reported in the prestigious journal Nature Communications.

“Living with CF is a journey of resilience, adaptation, and hope”

To mark Mother’s Day, we’re sharing the story of Ruth, who is mum to 18-year-old Lissy, who has cystic fibrosis (CF). Ruth gives her perspective on navigating daily life with cystic fibrosis, injecting fun and laughter into life, and being present for her younger daughter, Florrie, who doesn’t have CF. 

How the Government’s proposed benefits reform could impact people with cystic fibrosis (CF)

The Government has proposed significant changes to the benefits system. In this blog, we break down the key changes, and how we’ll continue to fight for a system that supports people affected by CF.

UK CF Medical Association Statement on Alyftrek

The CFMA welcomes the recent MHRA approval for the new triple CFTR modulator therapy, Alyftrek. This new medicine may offer an important alternative for some people with CF who are already treated with Kaftrio, with data from the clinical trials showing that it is comparable to Kaftrio at improving lung function. Alyftrek may also be an option for a small number of people who are not eligible for current therapies or have not been able to tolerate them, but current clinical trial data hasn’t revealed the specifics of this. While improvements to therapies is good news, ongoing challenges exist for people with the condition and CF clinical teams will continue to work to achieve excellent health outcomes and quality of life for all. CF remains a condition without a cure and we hope that new therapies will become available for people with CF in the future, particularly for those who do not respond to existing therapies.

Cystic Fibrosis Trust reacts to government benefits proposals

David Ramsden, Cystic Fibrosis Trust Chief Executive, said: "Benefits help many people with CF cover the additional costs of living with a life-limiting condition - from essential medical equipment to accessible transport for hospital appointments.

"We’re reviewing the potential impact of today’s government proposed changes to benefits and will share more over the coming days, but it’s important to note that these do not come in immediately and will go through discussion and consultation over the coming months before a final set of changes is confirmed.

"We will continue to campaign for a benefits system that understands and supports people with CF, and to provide specialist information and advice for everyone who needs it. If you are worried, please speak to your CF team or contact our Helpline."

Updated UK standards for the nursing management of cystic fibrosis published

Cystic fibrosis specialist nurse and Chair of the Cystic Fibrosis Nursing Association (CFNA) Working Group Caroline Whitton highlights the work of cystic fibrosis clinical nurse specialists (CF CNSs) and the importance of the updated guidelines.